Actively Recruiting
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Led by University Health Network, Toronto · Updated on 2026-03-06
80
Participants Needed
4
Research Sites
257 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
M
Medical College of Wisconsin
Collaborating Sponsor
AI-Summary
What this Trial Is About
The proposed study is a phase II, single arm, open-label trial of MR-guided radiation therapy (RT) with risk stratified RT dose selection in patients with anal cancer. Based on previous data, a risk adaptive treatment approached is proposed in 4 groups: Low risk, standard risk, intermediate risk, and high risk. Human papillomavirus (HPV) DNA will be analyzed to identify novel biomarkers that predict chemoradiotherapy (CRT) response and toxicity.
CONDITIONS
Official Title
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pathologically proven anal squamous cell carcinoma, including non-keratinizing histology such as basaloid or cloacogenic types
- Clinical stage T1-4 N0-1 M0 according to UICC/AJCC 8th Edition
- Eligible for definitive radiation therapy or chemoradiotherapy
- At least 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
You will not qualify if you...
- Previous chemotherapy, radiation therapy, or curative surgery (e.g., APR) for anal cancer
- Prior radiation therapy to the abdomino-pelvic area overlapping with current treatment volume
- History of another malignancy unless disease-free for at least 2 years and considered low risk for recurrence
- Exceptions include cervical cancer in situ and basal or squamous cell skin cancers diagnosed and treated within 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Allegheny Health Network
Pittsburgh, Pennsylvania, United States, 15212
Not Yet Recruiting
2
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States, 53226
Not Yet Recruiting
3
Austin Health
Heidelberg, Victoria, Australia, 3084
Not Yet Recruiting
4
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2C1
Actively Recruiting
Research Team
A
Ali Hosni
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here